基于基因突变的分子风险分层对甲状腺乳头状癌淋巴结转移的预测价值研究

Predictive value of gene mutations for lymph node metastasis in papillary thyroid carcinoma by using molecular risk group method

  • 摘要:
    背景 甲状腺乳头状癌(papillary thyroid carcinoma,PTC)患者总体预后良好,但部分患者会发生淋巴结转移,如何预测PTC淋巴结转移仍缺乏有效手段。
    目的 采用分子风险分层(molecular risk group,MRG)方法,探索PTC高危分子分型与淋巴结转移的相关性。
    方法 采用二代测序技术(next-generation sequencing,NGS)对2021年11月— 2024年3月于解放军总医院第一医学中心甲状腺(疝)外科进行手术的PTC患者术后标本进行基因检测,对39种基因变异进行分子风险分层,同时收集患者的临床病理学资料,进行淋巴结转移关联因素的Logistic回归,并对MRG评估效能进行分析。
    结果 共纳入74例PTC例患者,男性23例(31.1%),女性51例(68.9%);年龄17 ~ 69岁,发病年龄(40.16±12.59)岁。74例PTC患者完成177 panel基因联合检测,共检查出39种基因变异,其中SNV/Indel 37种,基因融合2种,基因变异率为100%,MRG高危分型38例(51.35%),低危分型36例(48.65%)。MRG分型与甲状腺乳头状癌临床病理学特征的关系分析显示有被膜侵犯与MRG高危分型显著相关(P=0.035)。多因素Logistic回归结果显示,MRG高危分型是PTC患者淋巴结转移、中央区淋巴结转移、侧颈区淋巴结转移的独立危险因素(OR=3.080、2.545、1.443,P<0.05)。配对四格表分析显示,患者MRG高危分型对淋巴结转移、中央区淋巴结转移、侧颈区淋巴结转移均有一定的评估效能(AUC=0.729、0.671、0.601)。统计推断显示,MRG高危分型与淋巴结转移/中央区淋巴结转移的关联性显著(P<0.05),但优势性亦全部显著(P<0.05),提示与金标准结果有一定差异。
    结论 本研究利用分子风险分层方法揭示了MRG高危分型与PTC中央区淋巴结转移相关,MRG高危分型可能是预测PTC中央区淋巴结转移的潜在指标,可以为术前评估PTC患者是否存在中央区淋巴结转移提供新的方法。

     

    Abstract:
    Background Patients with papillary thyroid carcinoma (PTC) generally have a favorable prognosis, but some may develop lymph node metastasis. However, effective methods for predicting lymph node metastasis in PTC are still lacking.
    Objective To explore the correlation between high-risk molecular subtypes of PTC and lymph node metastasis (LNM) by molecular risk group (MRG).
    Methods Genetic testing was performed using next-generation sequencing technology (NGS) on postoperative specimens of PTC patients who underwent surgery in the Department of Thyroid (Hernia) Surgery, the First Medical Center of PLA General Hospital from November 2021 to March 2024. Molecular risk stratification was performed for 39 genetic variants, while clinicopathological data of the patients were collected. Logistic regression analysis was conducted to identify factors associated with lymph node metastasis, and the predictive performance of the molecular risk gene (MRG) was evaluated.
    Results A total of 74 PTC patients were enrolled, including 23 males (31.1%) and 51 females (68.9%). The age ranged from 17 to 69 years, with a median age of (40.16±12.59) years. A total of 39 gene mutations were detected in 74 PTC patients, including 37 SNV/Indel and 2 fusion genes, with a mutation rate of 100%. MRG high-risk classification was found in 38 cases (51.35%) and low-risk classification in 36 cases (48.65%). The relationship between MRG classification and clinicopathological features of papillary thyroid carcinoma showed that the presence of capsular invasion was significantly related to MRG high-risk classification (P=0.035). Multivariate Logistic regression analysis showed that MRG high-risk classification was an independent risk factor for LNM/CLNM/LLNM in PTC patients (OR=3.080/2.545/1.443, P < 0.05). Paired four-grid table analysis showed that MRG high-risk classification had a certain evaluation efficacy for lymph node metastasis, central lymph node metastasis and lateral cervical lymph node metastasis, and the AUC was 0.729, 0.671 and 0.601, respectively. Statistical inference showed that MRG high-risk classification was significantly associated with lymph node metastasis/central lymph node metastasis (P < 0.05), but the dominance (difference test) was also significant (P < 0.05), suggesting that it was different from the gold standard.
    Conclusion MRG high-risk classification is associated with central lymph node metastasis in PTC by molecular risk stratification method. MRG high-risk classification may be a potential indicator for predicting central lymph node metastasis in PTC, which is a new method for preoperative evaluation of central lymph node metastasis in PTC patients.

     

/

返回文章
返回